Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.

Ann Hematol · 2023 · PMC10113291 · PMID 36944847

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Among patients who switched to ruxolitinib, some experienced improvements in symptoms that contributed to a positive trend in symptom control at week 16 compared with HU; however, this did not meet statistical significance [ 20 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.